Beam Therapeutics (BEAM) Income Statement
Is this a real, growing, cash-generative business, or a story propped up by accounting?
46 figures withheld by our checks. Each blank figure names its reason.
64.2mn → 98.9mn diluted shares since FY21. Rising share count dilutes EPS. Growth must outrun it.
▲67% YoY in FY25, largest jump in this window; watch free-cash-flow conversion.
$0.0M returned vs $−360.0M of FCF in FY25. Free cash flow was negative, so returns were funded from the balance sheet rather than from cash generation.
-57¢ of every revenue dollar becomes profit.
Net margin -57.2% is below the sector median.
| Line item | TTM † | FY25 | FY24 | FY23 | FY22 | FY21 | YoY | CAGR 21→25 |
|---|---|---|---|---|---|---|---|---|
| Revenue & profitability | ||||||||
Revenue | 146,644.0 | 139,743.0 | 63,518.0 | 377,709.0 | 60,920.0 | 51,844.0 | ▲120.0% | +28.1% |
Cost of revenue | — | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | — | — |
Gross profit | —A | —A | —A | —A | —A | 51,844.0 | — | — |
Research & development | 409,005.0 | 409,618.0 | 367,561.0 | 437,381.0 | 311,594.0 | 387,087.0 | ▲11.4% | +1.4% |
Selling, general & admin | 130,174.0 | 113,818.0 | 111,525.0 | 116,813.0 | 87,805.0 | 57,222.0 | ▲2.1% | +18.8% |
Total operating expenses | 539,152.0 | 523,436.0 | 479,086.0 | 554,194.0 | 399,399.0 | 444,309.0 | ▲9.3% | +4.2% |
Operating incomefeeds ROC rank | −392,535.0 | −383,693.0 | −415,568.0 | −176,485.0 | −338,479.0 | −392,465.0 | ▲7.7% | — |
Other income, net | 284,181.0 | 303,701.0 | 38,865.0 | 45,324.0 | 78,301.0 | 21,827.0 | — | — |
Pretax income | −108,354.0 | −79,992.0 | −376,703.0 | −131,161.0 | −260,178.0 | −370,638.0 | ▲78.8% | — |
Income tax | — | 0.0 | 39.0 | 1,366.0 | 3,410.0 | 0.0 | — | — |
Net incomePiotroski ROA ✕feeds Buffett Quality owner earnings | −108,354.0 | −79,992.0 | −376,742.0 | −132,527.0 | −289,088.0 | −370,638.0 | ▲78.8% | — |
| Per share | ||||||||
Diluted EPSbuyback-sensitive | −0.85 | −0.81 | −4.58 | −1.72 | −4.13 | −5.77 | ▲82.3% | — |
Diluted shares (mn) | 104.70 | 98.91 | 82.31 | 77.15 | 70.02 | 64.23 | ▲20.2% | +11.4% |
| Margins | ||||||||
Gross margin | —A | —A | —A | —A | —A | 100.0% | — | — |
Operating margin | −267.7% | −274.6% | −654.3% | −46.7% | −555.6% | −757.0% | ▲379.7pp | +482.4pp |
Net margin10th pct in Healthcare | −73.9% | −57.2% | −593.1% | −35.1% | −474.5% | −714.9% | ▲535.9pp | +657.7pp |
Statements normalized in our fundamentals DB · Not investment advice.
Common questions
What was Beam Therapeutics' revenue last fiscal year?
Beam Therapeutics reported revenue of $139.7M in fiscal 2025, up 120.0% from fiscal 2024.
What was Beam Therapeutics' net income?
Beam Therapeutics reported net income of −$80.0M in fiscal 2025, a net margin of −57.2%.

